childhood ependymoma
childhood ependymoma
Explore linked clinical trials. Standard reference: MONDO:00034785 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Histiocytosis, Langerhans-Cell, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, central nervous system cancer, childhood ependymoma, ependymoma, epithelial neoplasm, glioma, hepatoblastoma, hereditary disease, hereditary neoplastic syndrome, histiocytosis, immune system disorder, immunoproliferative disorder, interstitial lung disease, kidney cancer, kidney disorder, lung disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, medulloblastoma, mixed neoplasm, neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor, respiratory system disorder, rhabdoid tumor, urinary system disorder | Active, not recruiting | Phase 2 | 2026-09-22 | NCT03210714 | |
| Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, bone marrow disorder, childhood ependymoma, hematologic disorder, histiocytosis, immune system disorder, immunoproliferative disorder, interdigitating dendritic cell sarcoma, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, malignant histiocytosis, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2026-08-26 | NCT05857969 | |
| Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma | Colorectal Neoplasms, Hereditary Nonpolyposis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA repair disease, Digestive System Diseases, Digestive System Neoplasms, Lynch syndrome, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Nutritional and Metabolic Diseases, brain disorder, brainstem cancer, central nervous system cancer, central nervous system disorder, childhood ependymoma, colonic disorder, colorectal neoplasm, diffuse intrinsic pontine glioma, digestive system disorder, digestive system neoplasm, ependymoma, epithelial neoplasm, glioma, hereditary disease, hereditary neoplastic syndrome, intestinal disorder, malignant glioma, medulloblastoma, metabolic disease, mismatch repair cancer syndrome, mismatch repair cancer syndrome 1, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 1 | 2026-07-20 | NCT02359565 | |
| Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents | childhood ependymoma | Recruiting | Not stated | 2026-06-04 | NCT05151718 | |
| An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma | childhood ependymoma | Recruiting | Phase 2 / Phase 3 | 2024-04-26 | NCT02265770 |